EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSCHOG00000007869
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSCHOG00000006869
Gene Symbol: SCN3A
1 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSCHOG00000007771
Gene Symbol: SCN7A
1 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCHOG00000012301
Gene Symbol: SCN8A
1 Cross references
276 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSCHOG00000001870
Gene Symbol: SCN9A
1 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCHOG00000002317
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCHOG00000003838
Gene Symbol: SLC18A2
1 Cross references
222 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCHOG00000005940
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSCHOG00000000426
Gene Symbol: SLC6A4
1 Cross references
205 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSCHOG00000012982
Gene Symbol: SSTR2
1 Cross references
264 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSCHOG00000000164
Gene Symbol: SYK
1 Cross references
203 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSCHOG00000011302
Gene Symbol: SOAT1
1 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).